Title

Androgens and Alzheimer's Disease

Document Type

Journal Article

Publisher

Lippincott Williams & Wilkins

Faculty

Computing, Health and Science

School

Exercise, Biomedical and Health Science, Centre for Alzheimer's Disease

RAS ID

9037

Comments

This article was originally published as: Drummond, E., Harvey, A., & Martins, R. N. (2009). Androgens and Alzheimer's Disease. Current Opinion in Endocrinology, Diabetes and Obesity, 16(3), 254-259. Original article available here

Abstract

Purpose of review: To discuss the relationship between androgens, cognition and Alzheimer's disease. Recent findings: It has been found that low circulating levels of androgens are a risk factor for Alzheimer's disease. Decreased circulating androgens are also associated with declining cognitive performance, particularly in memory-related tasks. Conversely, androgen supplementation to hypogonadal men results in improved memory performance. It has therefore been hypothesized that androgen supplementation may be beneficial in Alzheimer's disease. In recent studies, animal models have been used to elucidate the molecular mechanism behind this relationship between androgens and Alzheimer's disease. These studies have shown that androgen depletion results in increased levels of beta amyloid and hyperphosphorylated tau, changes which are thought to be associated with subsequent neuronal death. Summary: Androgen depletion results in molecular changes associated with Alzheimer's disease. Further human trials are needed to determine whether androgen modulating therapy for Alzheimer's disease has clinical significance.

DOI

10.1097/MED.0b013e32832b101f

 

Link to publisher version (DOI)

10.1097/MED.0b013e32832b101f